AR119056A2 - Péptido de fusión, polinucleótido que lo codifica, vector y célula transformada - Google Patents

Péptido de fusión, polinucleótido que lo codifica, vector y célula transformada

Info

Publication number
AR119056A2
AR119056A2 ARP200101538A ARP200101538A AR119056A2 AR 119056 A2 AR119056 A2 AR 119056A2 AR P200101538 A ARP200101538 A AR P200101538A AR P200101538 A ARP200101538 A AR P200101538A AR 119056 A2 AR119056 A2 AR 119056A2
Authority
AR
Argentina
Prior art keywords
vector
transformed cell
fusion peptide
encoding polynucleotide
isoform
Prior art date
Application number
ARP200101538A
Other languages
English (en)
Inventor
Ricardo Alfredo Dewey
Zamora Benito Jorge Velasco
Tania Melina Rodriguez
Alejandra Carrea
Andrea Nancy CHISARI
Marcelo Javier Perone
Original Assignee
Consejo Nacional De Investigaciones Cientificas Y Tecn Conicet
Fund Articular
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Consejo Nacional De Investigaciones Cientificas Y Tecn Conicet, Fund Articular filed Critical Consejo Nacional De Investigaciones Cientificas Y Tecn Conicet
Publication of AR119056A2 publication Critical patent/AR119056A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Una isoforma del receptor II de TGFb que comprende una secuencia de alrededor de 80 aminoácidos y carece del dominio transmembrana; en donde la isoforma es agonista de TGFb-1. La isoforma comprende a la secuencia de aminoácidos SEQ ID Nº 12. La isoforma puede tener la secuencia de aminoácidos SEQ ID Nº 2 o secuencias que tienen al menos un 85% de identidad de secuencia con la secuencia SEQ ID Nº 2.
ARP200101538A 2013-12-19 2020-05-29 Péptido de fusión, polinucleótido que lo codifica, vector y célula transformada AR119056A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361917974P 2013-12-19 2013-12-19

Publications (1)

Publication Number Publication Date
AR119056A2 true AR119056A2 (es) 2021-11-17

Family

ID=53403721

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP140104755A AR098827A1 (es) 2013-12-19 2014-12-18 ISOFORMA DEL RECEPTOR II DE TGF-b, POLINUCLEÓTIDOS QUE LA CODIFICAN VECTORES, CÉLULAS TRANSFORMADAS, PÉPTIDOS Y DE FUSIÓN, MÉTODO Y USOS
ARP200101538A AR119056A2 (es) 2013-12-19 2020-05-29 Péptido de fusión, polinucleótido que lo codifica, vector y célula transformada

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP140104755A AR098827A1 (es) 2013-12-19 2014-12-18 ISOFORMA DEL RECEPTOR II DE TGF-b, POLINUCLEÓTIDOS QUE LA CODIFICAN VECTORES, CÉLULAS TRANSFORMADAS, PÉPTIDOS Y DE FUSIÓN, MÉTODO Y USOS

Country Status (5)

Country Link
US (1) US10233227B2 (es)
EP (1) EP3082846B1 (es)
AR (2) AR098827A1 (es)
ES (1) ES2749615T3 (es)
WO (1) WO2015095628A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR107780A1 (es) * 2016-11-14 2018-06-06 Consejo Nacional De Investigaciones Cientificas Y Tecn Conicet Método para determinar la actividad de enfermedades autoinmunes y kit
EP3762421A2 (en) 2018-03-09 2021-01-13 Agenus Inc. Anti-cd73 antibodies and methods of use thereof
CN110372800B (zh) * 2019-08-27 2022-06-07 南京安吉生物科技有限公司 具有多功能活性的融合多肽及其应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4124815B2 (ja) 1991-10-31 2008-07-23 ホワイトヘッド インスティチュート フォー バイオメディカル リサーチ ＴＧＦ−β型受容体ｃＤＮＡおよびその用途
US6008011A (en) 1991-10-31 1999-12-28 Whitehead Institute For Biomedical Research TGF-β type II receptor cDNAs
US6395494B1 (en) * 1993-05-13 2002-05-28 Neorx Corporation Method to determine TGF-β
ES2174868T3 (es) 1992-10-29 2002-11-16 Celtrix Pharma Fragmento del receptor de fijacion a tgf-beta tipoii como agente terapeutico.
BR9808934A (pt) 1997-04-18 2000-08-01 Biogen Inc Proteìnas de fusão de região constante de receptor/imunoglobulina tgf-beta do tipo ii
JP2001206899A (ja) * 1999-11-18 2001-07-31 Japan Tobacco Inc ＴＧＦ−βＩＩ型受容体に対するヒトモノクローナル抗体及びその医薬用途
US20030028905A1 (en) * 2001-07-31 2003-02-06 Petra Knaus Mutant forms of the TGF-beta type II receptor which bind all TGF-beta isoforms
AU2002357362A1 (en) * 2001-12-21 2003-07-30 The Regents Of The University Of California USE OF SOLUBLE TYPE II TGF-Beta RECEPTOR TO SUPPRESS PANCREATIC CANCER GROWTH AND METASTASIS
EP2171062A1 (en) 2007-06-15 2010-04-07 Genzyme Corporation Fusion proteins containing two tgf-beta binding domains of tgf-beta type ii receptor
CN102850458B (zh) * 2011-06-28 2014-10-01 华博生物医药技术（上海）有限公司 新型重组双功能融合蛋白及其制法和用途

Also Published As

Publication number Publication date
ES2749615T3 (es) 2020-03-23
EP3082846B1 (en) 2019-07-17
WO2015095628A1 (en) 2015-06-25
US10233227B2 (en) 2019-03-19
EP3082846A4 (en) 2017-09-20
AR098827A1 (es) 2016-06-15
WO2015095628A8 (en) 2016-09-29
US20160318989A1 (en) 2016-11-03
EP3082846A1 (en) 2016-10-26

Similar Documents

Publication Publication Date Title
AR119056A2 (es) Péptido de fusión, polinucleótido que lo codifica, vector y célula transformada
CL2017001070A1 (es) Variantes de interferon a2b
ES2545895T3 (es) Proteína de fusión anticancerígena
NZ731571A (en) T cell receptors
EA201691111A1 (ru) Химерные белки фактора viii и их применение
EA201491049A1 (ru) Противораковый слитый белок
ES2691070T3 (es) Péptidos antiinflamatorios y composición que comprende los mismos
CY1119916T1 (el) Ανοσογονικη συνθεση
EA201270517A1 (ru) Микобактериальные вакцины
EA201491277A1 (ru) Противораковый слитый белок
UA118167C2 (uk) Пептид та його застосування
PE20170955A1 (es) Nuevas proteinas inhibidoras de insectos
EA201391005A1 (ru) Слитый белок против злокачественной опухоли
AR102410A1 (es) Polipéptidos que tienen actividad xilanasa con una tasa de conversión alta de polisacáridos que contienen xilosa
AR110093A1 (es) D-psicosa 3-epimerasa y método para preparar d-psicosa utilizando la misma
NZ706884A (en) Fc gamma receptor iib variants
AR120721A2 (es) Péptidos y composiciones para el tratamiento de daño articular
AR128395A2 (es) Péptidos novedosos capaces de inducir la formación de anticuerpos contra pcsk9
CO2017011431A2 (es) Proteínas de fusión de receptor de factor de crecimiento epidermal variante iii - mesotelina
EA201691011A1 (ru) Последовательность модифицированного эндолизина el188
WO2015107363A3 (en) Mycobacterial antigen composition
EA201492068A1 (ru) Гидрохлоридная соль пептида и ее применение в комбинации с другими пептидами в иммунотерапии
EA201391546A1 (ru) Противораковый слитый белок
MX2022008298A (es) Anticuerpo para sesgar proporciones de sexos y metodos de uso del mismo.
CU24609B1 (es) Proteína de fusión que comprende una proteína de subunidad de ferritina monomérica unida a una proteína de dominio alfa 3 de mic